Related Experiment Video
Updated: May 9, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Myelodysplastic syndromes: clinical practice guidelines in oncology
Peter L Greenberg1, Eyal Attar, John M Bennett
1Stanford Cancer Institute, USA.
Abstract:
The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.
More Related Videos
Related Concept Videos
Cellular Adaptation IV: Dysplasia and Metaplasia
Standards of Care II
Standards of Care I

